AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05546515
Drug: Suvorexant (dual orexin receptor antagonist)
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be prescribed up to 30 days of SUVO.
Trial: NCT05607342
Drug: Osanetant
RxNorm normalized name: Osanetant
DrugBank: Osanetant (DB04872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the effect of Osanetant on the testosterone levels.
Trial: NCT06789900
Drug: Everolimus (Afinitor®)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral dose of everolimus 5 mg once a week for 24 weeks
Trial: NCT06300658
Drug: Stellate ganglion block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive preemptive stellate ganglion block (SGB) just before spinal anesthesia.
Trial: NCT06598917
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request.
Trial: NCT06600841
Drug: Immunotherapy（Adebrelimab）
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.
Trial: NCT06600841
Drug: immunotherapy（Adebrelimab）
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-L1
Trial: NCT06093126
Drug: Lemborexant 5 MG
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg
Trial: NCT05330130
Drug: Follitropin beta injection 150 IU
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Trial: NCT05330130
Drug: Follitropin beta injection 300 IU
RxNorm normalized name: follitropin beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Trial: NCT06785337
Drug: Inhaled nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitroglycerin
Trial: NCT05393791
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use of abiraterone or enzalutamide
Trial: NCT05393791
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of abiraterone or enzalutamide
Trial: NCT06145321
Drug: G-CSF administration (bolus injection versus intravenous infusion)
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)
Trial: NCT06614881
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Precedex, 100 µg/ml) was provided as an intravenous (IV) loading dose of 1 µg/kg over 10-min
Trial: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
RxNorm normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusions were prepared to provide 0.5 µg/kg/h
Trial: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
RxNorm normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusions were prepared to provide 0.7 µg/kg/h
Trial: NCT06614881
Drug: Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
RxNorm normalized name: dexmedetomidine in 0.9 % NaCl 1,000 mcg/250 mL (4 mcg/mL) INTRAVEN INFUSION BOTTLE (ML)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine infusions were prepared to provide 1.1 µg/kg/h
Trial: NCT06538480
Drug: PRGN-2012
RxNorm normalized name: PRGN-2012
DrugBank: PRGN-2012 (DB18342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
Trial: NCT06766019
Drug: Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. adebrelimab 1200mg, i.v. D1, q28d~2. irinotecan liposomal (II) 60mg/m\^2, i.v. D1, Q2W~3. oxaliplatin 85mg/m\^2, i.v. D1, Q2W~4. 5-FU/LV 2400mg/400mg/m\^2, i.v. D1, Q2W 4-week cycles, 6 cycles
Trial: NCT06765330
Drug: CHX disinfection
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each CHX cavity will be treated with disinfectant with a disposable micro brush tip and left undisturbed for 20 seconds. They will then be air-dried for 10 seconds and restore the tooth.
Trial: NCT04409639
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
Trial: NCT05587036
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin oral tablet, 550 mg, twice daily, two-weeks
Trial: NCT05845424
Drug: High intensity statin plus ezetimibe therapy
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg + Ezetimibe 10 mg
Trial: NCT05611801
Drug: marstacimab
RxNorm normalized name: Marstacimab
DrugBank: Marstacimab (DB17725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marstacimab
Trial: NCT06302348
Drug: Sepiapterin
RxNorm normalized name: Sepiapterin
DrugBank: Sepiapterin (DB16326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
Trial: NCT05491811
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Ensartinib 225 mg oral once daily from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Trial: NCT05491811
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 7.5 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks) from baseline until disease progression, unacceptable toxicity, withdrawal of consent or death.
Trial: NCT05370495
Drug: SY-201 Ophthalmic Solution Vehicle
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SY-201 Ophthalmic Solution Vehicle
Trial: NCT05453552
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Trial: NCT06009653
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
Trial: NCT05453552
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Trial: NCT05453552
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
Trial: NCT05453552
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Trial: NCT05453552
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
Trial: NCT06400160
Drug: TB511
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
Trial: NCT06400160
Drug: Keytruda
RxNorm normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
Trial: NCT06541574
Drug: Sham Injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Injection
Trial: NCT06594172
Drug: Memantine Oral Tablet
RxNorm normalized name: memantine Oral Tablet
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Memantine Tablets (10mg/tablet):~Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily.
Trial: NCT06594172
Drug: Pioglitazone 15mg
RxNorm normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet):~Weeks 1-24: 30mg once daily.
Trial: NCT06592170
Drug: Linperlisib combination with obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safe import period: Linperlisib: 80 mg, oral (pre - and post meal), QD; obinutuzumab: 1000 mg, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there is one cycle in total.~Extended treatment period: Combination induction: Linperlisib: RP2D, oral (pre - and post meal), QD; obinutuzumab: 1000 mg/time, intravenous infusion, administered on the first day (1st cycle on days 1, 8, and 15); Every 28 days, there are 2 cycles in total. Afterwards, single drug maintenance: Linperlisib: RP2D, oral (before and after meals), QD; every 28 days per cycle.
Trial: NCT04606914
Drug: mirvetuximab soravtansine (MIRV; IMGN853)
RxNorm normalized name: mirvetuximab soravtansine
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
Trial: NCT06587698
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg QD for 3 month
Trial: NCT06587698
Drug: Sitagliptin+BeiDouGen
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month
Trial: NCT04883281
Drug: cisplatin, cetuximab, or carboplatin-paclitaxel
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Trial: NCT05279755
Drug: prosetin
RxNorm normalized name: Prosetin
DrugBank: Prosetin (DB18649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT05485896
Drug: Pembrolizumab plus Lenvatinib
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive treatment with Pembrolizumab in combination with Lenvatinib every 3 weeks for 3 cycles in the preoperation. Additional 17 cycles of Pembrolizumab were needed for patients with high risk of recurrence (tumor stage 2 with nuclear grade IV or sarcomatoid differentiation, tumor stage 3 or higher, regional lymph-node metastasis, or stage M1 with no evidence of disease residual).
Trial: NCT06547619
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Trial: NCT06272487
Drug: Zilebesiran
RxNorm normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilebesiran administered by subcutaneous (SC) injection
Trial: NCT04896086
Drug: VRC-GENADJ0110-AP-NV (Adjuplex)
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuplex is a sterile, pyrogen-free adjuvant solution produced by the VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline. Adjuplex adjuvant was mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B.
Trial: NCT04896086
Drug: VRC-FLUMOS0111-00-VP (FluMos-v1)
RxNorm normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FluMos-v1 investigational vaccine is composed of engineered pentameric promoters based on C. albicans lumazine synthase assembled with 20 trimeric promoters displaying HA ectodomains. It contains hemagglutinin (HA) proteins from the following 4 influenza strains: A/Idaho/07/2018, A/Perth/1008/2019, B/Colorado/06/2017 and B/Phuket/3073/2013.
Trial: NCT06599775
Drug: Adebrelimab injection
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
Trial: NCT06599775
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
Trial: NCT06599775
Drug: Carboplatin injection
RxNorm normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
Trial: NCT04808505
Drug: Miglustat
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 65 mg oral capsules
Trial: NCT05175352
Drug: Cendakimab
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05685537
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of levosimendan 48 hours before surgery
Trial: NCT06745154
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given nicotine patches, gum, or lozenges
Trial: NCT06056895
Drug: Tuparstobart
RxNorm normalized name: Tuparstobart
DrugBank: Tuparstobart (DB19118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06056895
Drug: Verzistobart
RxNorm normalized name: Verzistobart
DrugBank: Verzistobart (DB18895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05030831
Drug: INZ-701
RxNorm normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Trial: NCT04468776
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem, as prescribed by physician
Trial: NCT04468776
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trazodone, as prescribed by physician
Trial: NCT05687903
Drug: TAK-861
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-861 oral tablets
Trial: NCT05338086
Drug: MB09 (denosumab biosimilar)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pre-filled syringe (PFS) 60 mg/mL solution, administered as subcutaneous injection
Trial: NCT05338086
Drug: EU-Prolia
RxNorm normalized name: Prolia
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PFS 60 mg/mL solution, administered as subcutaneous injection
Trial: NCT06705127
Drug: TORIPALIMAB INJECTION(JS001 )
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.
Trial: NCT04731467
Drug: CM-24 and Nivolumab - Dose Escalation
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors